carbostyril has been researched along with Tachyarrhythmia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galindo-Tovar, A; Kaumann, AJ; Vargas, ML | 2 |
| Decramer, ML; Hanania, NA; Lötvall, JO; Yawn, BP | 1 |
| Calzadilla, SV; Cox, BF; Fryer, RM; Gopalakrishnan, M; Hu, Y; Lin, CT; Marsh, KC; Preusser, LC; Reinhart, GA; Xu, H | 1 |
1 review(s) available for carbostyril and Tachyarrhythmia
| Article | Year |
|---|---|
The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Blood Glucose; Cough; Ethanolamines; Formoterol Fumarate; Headache; Humans; Indans; Nasopharyngitis; Potassium; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Tract Infections; Salmeterol Xinafoate; Spasm; Tachycardia; Tremor | 2013 |
3 other study(ies) available for carbostyril and Tachyarrhythmia
| Article | Year |
|---|---|
Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (-)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Agonists; Animals; Arrhythmia, Sinus; Atrial Function, Left; Atrial Function, Right; Bradycardia; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Partial Agonism; Female; Heart Atria; Heart Rate; In Vitro Techniques; Isoproterenol; Male; Myocardial Contraction; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Propanolamines; Quinolones; Rats; Rats, Sprague-Dawley; Rolipram; Stimulation, Chemical; Tachycardia | 2009 |
Function of cardiac beta1- and beta2-adrenoceptors of newborn piglets: role of phosphodiesterases PDE3 and PDE4.
Topics: Adrenergic Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Epinephrine; Heart Atria; Heart Ventricles; In Vitro Techniques; Norepinephrine; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Quinolones; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Rolipram; Sinoatrial Node; Swine; Tachycardia | 2010 |
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine.
Topics: Adenosine Triphosphate; Amides; Animals; Benzophenones; Blood Pressure; Cyclic S-Oxides; Cyclobutanes; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electrocardiography; Heart Rate; Hypotension; Infusions, Intravenous; Ion Channel Gating; Male; Muscle Contraction; Muscle, Smooth; Nifedipine; Nitriles; Pharmaceutical Vehicles; Polyethylene Glycols; Potassium Channels; Quinolones; Tachycardia; Urinary Bladder; Urinary Incontinence; Vascular Resistance | 2004 |